Moderna shares double on Phase 3 melanoma vaccine success with Merck partner, sparking analyst upgrades and short‑seller losses

SentiSense · Published · Updated

Moderna announced that its Phase 3 melanoma vaccine, developed with Merck, significantly cut recurrence rates compared with Keytruda alone, sending th...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis